Damora Therapeutics changes independent auditor

Damora Therapeutics, Inc. changed its independent auditor.

Rhea-AI Filing Summary

Damora Therapeutics, Inc. changed its independent auditor. On April 17, 2026, the Audit Committee dismissed EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm and appointed Ernst & Young LLP (EY US) effective immediately.

EY Denmark’s reports on the Company’s financial statements for 2025 and 2024 contained no adverse or qualified opinions, although the 2024 report included an explanatory paragraph about the Company’s ability to continue as a going concern. The Company reports no disagreements or reportable events with EY Denmark and states that it did not consult EY US on accounting or auditing matters before the engagement.

Insights

Equity research analyst – corporate governance focus

Auditor switch with no reported disputes keeps this a governance, not earnings, story.

The Audit Committee of Damora Therapeutics replaced its long‑time auditor EY Denmark with Ernst & Young LLP (EY US), effective April 17, 2026. EY Denmark’s opinions on the 2025 and 2024 financials were clean aside from a going concern explanatory paragraph for 2024.

The company explicitly notes there were no disagreements or reportable events with EY Denmark and that it had not previously consulted EY US on specific accounting treatments or opinions. That framing points to an administrative or strategic change in audit provider rather than a response to a disclosed dispute over accounting or disclosure.

The prior going concern explanatory paragraph in the 2024 opinion was already known from those financials and is not new here. Future annual and quarterly reports will show whether EY US modifies audit emphasis or going concern language, which could further clarify the company’s financial risk profile.

8-K Event Classification

2 items: 4.01, 9.01

2 items

Item 4.01 Changes in Registrant's Certifying Accountant Governance

The company changed its independent auditing firm, which may involve disagreements on accounting matters.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Auditor dismissal date: April 17, 2026 Going concern year: Fiscal year ended December 31, 2024

2 metrics

Auditor dismissal date April 17, 2026 Date EY Denmark was dismissed by the Audit Committee

Going concern year Fiscal year ended December 31, 2024 Year whose audit report included a going concern explanatory paragraph

Key Terms

independent registered public accounting firm, going concern, reportable events, Regulation S-K, +1 more

5 terms

independent registered public accounting firm financial

"dismissed EY Denmark as the Company’s independent registered public accounting firm, effective immediately"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

going concern financial

"report for the fiscal year ended December 31, 2024 contained an explanatory paragraph related to the Company’s ability to continue as a going concern"

Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.

reportable events regulatory

"there were (i) no disagreements ... and (ii) no reportable events (as described in Item 304(a)(1)(v) of Regulation S-K)"

Reportable events are significant incidents or changes a company is legally required to disclose to regulators and the public, such as major safety problems, legal actions, financial irregularities, or management changes. They matter to investors because these events can alter a company’s risk profile or future performance, much like a dashboard warning light signals a problem that could affect a car’s safety or reliability. Timely disclosure helps investors make informed decisions and maintain market fairness.

Regulation S-K regulatory

"no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto)"

A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.

Audit Committee financial

"the Audit Committee (the “Audit Committee”) of the Board of Directors"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change in auditors did Damora Therapeutics (DMRA) disclose?

Damora Therapeutics’ Audit Committee dismissed EY Denmark as its independent registered public accounting firm and appointed Ernst & Young LLP (EY US), effective April 17, 2026. EY Denmark had served as the company’s auditor since 2019 before this change in engagement.

Did EY Denmark issue any adverse opinions on Damora Therapeutics (DMRA)?

EY Denmark’s reports on Damora Therapeutics’ 2025 and 2024 consolidated financial statements contained no adverse opinions or disclaimers and were not qualified. However, the 2024 report included an explanatory paragraph highlighting substantial doubt about the company’s ability to continue as a going concern.

Were there disagreements with EY Denmark before Damora Therapeutics (DMRA) changed auditors?

The company states there were no disagreements with EY Denmark on accounting principles, financial statement disclosure, or audit scope during 2024, 2025, or the interim period to April 17, 2026. It also reports no reportable events under Item 304(a)(1)(v) of Regulation S‑K during that timeframe.

Did Damora Therapeutics (DMRA) consult EY US before appointing it as auditor?

Damora Therapeutics reports that neither it nor anyone on its behalf consulted EY US during 2024, 2025, or through April 17, 2026 on applying accounting principles, expected audit opinions, or any disagreement or reportable event. EY US was engaged without prior advisory consultations described in the filing.

What going concern disclosure affected Damora Therapeutics (DMRA) in 2024?

EY Denmark’s audit report on Damora Therapeutics’ 2024 consolidated financial statements included an explanatory paragraph about the company’s ability to continue as a going concern. This highlighted substantial doubt regarding ongoing operations, even though the overall opinion was not adverse or otherwise qualified.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/20/2026 - 04:00 PM Learn about SEC filing dates

0001800315false00018003152026-04-172026-04-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 17, 2026

DAMORA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39655		37-1957007
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)
		221 Crescent Street Building 23, Suite 105 Waltham, MA 02453 (Address of principal executive offices, including zip code)
		(781) 281-9020 (Registrant’s telephone number, including area code)
		(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		DMRA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.01 Changes in Registrant’s Certifying Accountant.

(a) Dismissal of Independent Registered Public Accounting Firm

On April 17, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), dismissed EY Godkendt Revisionspartnerselskab (“EY Denmark”) as the Company’s independent registered public accounting firm, effective immediately. EY Denmark served as the independent registered public accounting firm of the Company since 2019.

The reports of EY Denmark on the consolidated financial statements of the Company for the fiscal years ended December 31, 2025 and 2024 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that such report for the fiscal year ended December 31, 2024 contained an explanatory paragraph related to the Company’s ability to continue as a going concern.

During the Company’s two most recent fiscal years ended December 31, 2025 and 2024 and the subsequent interim period from January 1, 2026 to April 17, 2026, there were (i) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) with EY Denmark on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of EY Denmark, would have caused it to make reference to the subject matter of the disagreement in connection with its report and (ii) no reportable events (as described in Item 304(a)(1)(v) of Regulation S-K).

The Company provided EY Denmark with a copy of the disclosures made in this Item 4.01 and requested EY Denmark to furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made by the Company and, if not, stating the respects in which it does not agree. A copy of EY Denmark’s letter to the SEC dated April 17, 2026 regarding these statements is filed as Exhibit 16.1 to this Current Report on Form 8-K.

(b) Appointment of New Independent Registered Public Accounting Firm

On April 17, 2026, the Audit Committee engaged Ernst & Young LLP (“EY US”) as the Company’s independent registered public accounting firm, effective immediately.

During the Company’s two most recent fiscal years ended December 31, 2025 and 2024 and the subsequent interim period from January 1, 2026 to April 17, 2026, neither the Company nor anyone on its behalf consulted EY US regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that EY US concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description of Document
16.1		Letter from EY Godkendt Revisionspartnerselskab, dated April 17, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Damora Therapeutics, Inc.
Date: April 20, 2026				By:		/s/ Sherwin Sattarzadeh
						Sherwin Sattarzadeh
						Chief Operating Officer

Filing Exhibits & Attachments

2 documents

Other Documents

• EX-16.1 EX-16.1 5.2 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 27.3 KB